Zanidatamab

泽尼达妥单抗

Report date: 2026/05/20 20:02:01

Base Information

Drug NameZanidatamab
Drug Alias NameZani (BeiGene/Jazz Pharmaceuticals Inc/Zymeworks)zanidatamab-hriiZiihera百赫安ZW-25 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonistsPhagocytes stimulants
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsEsophageal adenocarcinomaMetastatic breast cancerGastroesophageal Junction Neoplasms +[21] 
Global Approved IndicationsBile Duct NeoplasmsBiliary Tract Neoplasms
Approved Indications in ChinaBile Duct Neoplasms
Original Approved Country/TerritoryUnited States
Original Approved Date2024/11/20
Country/TerritoryCzechiaBelgiumCanada +[41] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesZymeworks Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBeOne Medicines LtdThe University Of Texas MD Anderson Cancer CenterJazz Pharmaceuticals Inc +[8] 
Inactive CompaniesYonsei University
Active IndicationsEsophageal adenocarcinomaMetastatic breast cancerGastroesophageal Junction Neoplasms +[20] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG